Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutic (NQ: UTHR )

164.85 USD -4.50 (-2.66%)
Official Closing Price Updated: 4:37 PM EST, Jan 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about United Therapeutic

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease
INCREASE Study is First to Demonstrate a Clear Benefit in Patients with PH-ILD, a Life-threatening Disease with No Currently FDA-Approved Treatments 
From PR Newswire
United Therapeutics Corporation To Present At The 39th Annual J.P. Morgan Healthcare Conference
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the... 
From PR Newswire
Y-mAbs Announces Sale of Priority Review Voucher
From GlobeNewswire News Releases
United Therapeutics Announces Agreement To Acquire Priority Review Voucher
Voucher expected to be applied to the forthcoming NDA for Tyvaso DPI™ 
From PR Newswire
United Therapeutics Receives FDA Orphan Drug Designation For Treprostinil For The Treatment Of Idiopathic Pulmonary Fibrosis
Phase 3 TETON study planned in 2021 for Tyvaso® in patients with idiopathic pulmonary fibrosis 
From PR Newswire
United Therapeutics Releases Its First Corporate Responsibility Report
Report available at corporateresponsibility.unither.com 
From PR Newswire
United Therapeutics Corporation To Present At The Jefferies Virtual London Healthcare Conference
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the... 
From PR Newswire
United Therapeutics Corporation To Present At The Credit Suisse 29th Annual Virtual Healthcare Conference
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, will provide an overview and update on the... 
From PR Newswire
United Therapeutics Corporation Reports Third Quarter 2020 Financial Results
- Third quarter Orenitram® net revenue growth of 20% and Tyvaso® net revenue growth of 17% year-over-year 
From PR Newswire
United Therapeutics Highlights Poster Presentations from the Recent CHEST 2020 Meeting
Clinical study data suggests Tyvaso® improved forced vital capacity, an important measure of lung function, in patients with pulmonary hypertension associated with interstitial lung disease 
From PR Newswire
United Therapeutics Corporation To Report Third Quarter 2020 Financial Results Before The Market Opens On Wednesday, October 28, 2020
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2020 financial results before the market opens on Wednesday, October 28, 2020. 
From PR Newswire
United Therapeutics to Present New Tyvaso® Clinical and Treprostinil Real-World Data at CHEST Annual Meeting 2020
United Therapeutics Corporation (Nasdaq: UTHR) today announced it will present clinical trial data on Tyvaso® (treprostinil) Inhalation Solution in patients with pulmonary hypertension associated with... 
From PR Newswire
CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant
Expanded collaboration combines CollPlant's proprietary BioInk that is based on its recombinant human collagen (rhCollagen) technology and United Therapeutics' regenerative medicine and organ... 
From PR Newswire
United Therapeutics Corporation to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the... 
From PR Newswire
United Therapeutics Corporation Appoints Linda Maxwell to Its Board of Directors
United Therapeutics Corporation (Nasdaq: UTHR) announced today the appointment of Linda Maxwell, M.D. to its Board of Directors as an independent director, effective as of September 10, 2020. 
From PR Newswire
CollPlant Biotechnologies Reports Second Quarter (Q2) 2020 Financial Results
Increasing sales of BioInk for 3D Bioprinting and Medical Aesthetics 
From PR Newswire
United Therapeutics Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Tyvaso® For Pulmonary Hypertension Associated With Interstitial Lung Disease
United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental New Drug Application (sNDA) for Tyvaso®... 
From PR Newswire
United Therapeutics Corporation to Present at the Wedbush PacGrow Healthcare Virtual Conference
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Dr. Martine Rothblatt, Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the... 
From PR Newswire
United Therapeutics Corporation Reports Second Quarter 2020 Financial Results
- Second quarter Orenitram® revenue growth of 40% year-over-year 
From PR Newswire
United Therapeutics Corporation Asserts New Tyvaso Patent Against Liquidia
United Therapeutics Corporation (Nasdaq: UTHR) announced today the United States Patent and Trademark Office issued a new patent on July 21, 2020, relating to Tyvaso® (treprostinil) Inhalation... 
From PR Newswire
United Therapeutics Corporation To Report Second Quarter 2020 Financial Results Before The Market Opens On Wednesday, July 29, 2020
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2020 financial results before the market opens on Wednesday, July 29, 2020. 
From PR Newswire
United Therapeutics Announces Increase Data Presentation at an American Thoracic Society Virtual Session
United Therapeutics Corporation (Nasdaq: UTHR) announced today that key data from the INCREASE study of Tyvaso® (treprostinil) Inhalation Solution in patients suffering from World Health Organization... 
From PR Newswire
United Therapeutics Corporation Files Lawsuit Against Liquidia For Infringement Of Tyvaso Patents
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Liquidia Technologies, Inc. (Liquidia) for... 
From PR Newswire
United Therapeutics Corporation to Present at the Jefferies Virtual Health Care Conference
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the... 
From PR Newswire
United Therapeutics Corporation To Present At The BofA Securities Virtual Health Care Conference 2020
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the... 
From PR Newswire
United Therapeutics Corporation Reports First Quarter 2020 Financial Results
- First quarter Orenitram® net revenue growth of 18% year-over-year 
From PR Newswire
United Therapeutics Announces Additional Results From FREEDOM-EV Study Showing The Hemodynamic And Risk Status Reduction Benefits Of Orenitram Treatment In Patients With Pulmonary Arterial Hypertensio
- Orenitram demonstrated improvement in hemodynamic parameters and risk status, important indicators of long-term outcomes in PAH patients, in presentations at recent scientific conferences 
From PR Newswire
United Therapeutics Corporation to Report First Quarter 2020 Financial Results Before the Market Opens on Wednesday, April 29, 2020
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2020 financial results before the market opens on Wednesday, April 29, 2020. 
From PR Newswire
Celularity Expands Strategic Collaboration with United Therapeutics Corporation to COVID-19 Infection and Acute Respiratory Distress Syndrome
- The expanded strategic collaboration includes the use of Celularity's proprietary CYNK-001 for treatment of SARS-CoV-2 virus, which causes COVID-19 and Acute Respiratory Distress Syndrome 
From PR Newswire
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2019 Financial Results
~ Full year net revenue growth of 3% excluding Adcirca® ~ 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.